Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Semler Scientific, Inc. provides technology solutions to improve the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. Its products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, and family practitioners, as well as healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups. The company offers its products through salespersons and distributors. Semler Scientific, Inc. was incorporated in 2007 and is headquartered in Santa Clara, California.

Semler Scientific, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

NEW YORK AND NEW ORLEANS , DEC. 12, 2025 /PRNEWSWIRE/ -- FORMER ATTORNEY GENERAL OF LOUISIANA CHARLES C. FOTI, JR., ESQ.

SEMLER SCIENTIFIC INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: KAHN SWICK & FOTI, LLC INVESTIGATES ADEQUACY OF PRICE AND PROCESS IN PROPOSED SALE OF SEMLER SCIENTIFIC, INC. - SMLR

CAMPBELL, CALIF. , OCT. 28, 2025 /PRNEWSWIRE/ -- SEMLER SCIENTIFIC, INC. (NASDAQ: SMLR), THE SECOND U.S. PUBLIC COMPANY TO ADOPT BITCOIN AS ITS PRIMARY TREASURY RESERVE ASSET AND A LEADER IN MEDICAL DEVICES AND SOFTWARE TO COMBAT CHRONIC DISEASES, TODAY ANNOUNCED THAT DUE TO ITS PENDING TRANSACTION WITH STRIVE, INC., THE COMPANY WILL NOT BE HOSTING A CONFERENCE CALL OR PROVIDING AN ACCOMPANYING EARNINGS PRESENTATION IN CONJUNCTION WITH ITS THIRD QUARTER 2025 FINANCIAL RESULTS.

SEMLER SCIENTIFIC TO RELEASE THIRD QUARTER 2025 FINANCIAL RESULTS

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED SIGNIFICANT LOSSES IN SEMLER SCIENTIFIC TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU SUFFERED SIGNIFICANT LOSSES IN SEMLER SCIENTIFIC BETWEEN MARCH 10, 2021 AND APRIL 15, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 28, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SEMLER SCIENTIFIC, INC. ("SEMLER SCIENTIFIC" OR THE "COMPANY") (NASDAQ: SMLR) AND REMINDS INVESTORS OF THE OCTOBER 28, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

SMLR FINAL DEADLINE ALERT: FARUQI & FARUQI, LLP REMINDS INVESTORS OF THE SEMLER SCIENTIFIC UPCOMING LEAD PLAINTIFF DEADLINE ON TUESDAY, OCTOBER 28, 2025

BRAGAR EAGEL & SQUIRE, P.C. LITIGATION PARTNER BRANDON WALKER ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SEMLER (SMLR) TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SEMLERSCIENTIFIC SECURITIES BETWEEN MARCH 10, 2021 AND APRIL 15, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL BRAGAR EAGEL & SQUIRE PARTNERBRANDON WALKER OR MARION PASSMORE DIRECTLYAT (212) 355-4648.

SEMLER FINAL DEADLINE ALERT: BRAGAR EAGEL & SQUIRE, P.C. URGES SEMLER STOCKHOLDERS TO CONTACT THE FIRM BEFORE OCTOBER 28TH

NEW YORK--(BUSINESS WIRE)---- $SMLR #CLASSACTION--FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SEMLER SCIENTIFIC, INC. (SEMLER SCIENTIFIC OR THE COMPANY) (NASDAQ: SMLR) AND REMINDS INVESTORS OF THE OCTOBER 28, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY. FARUQI & FARUQI IS A LEADING NATIONAL SECURITIES LAW FIRM WITH OFFICES IN NEW YORK, PENNSYLVANIA, CALIFORNIA AND G.

SMLR 36 HOUR DEADLINE ALERT: FARUQI & FARUQI, LLP REMINDS INVESTORS OF THE SEMLER SCIENTIFIC UPCOMING LEAD PLAINTIFF DEADLINE ON TUESDAY, OCTOBER 28, 2025

LOS ANGELES , OCT. 27, 2025 /PRNEWSWIRE/ -- THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SEMLER SCIENTIFIC, INC. ("SEMLER " OR "THE COMPANY") (NASDAQ: SMLR ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SMLR DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

SEMLER SCIENTIFIC, INC. SUED FOR SECURITIES LAW VIOLATIONS - CONTACT THE DJS LAW GROUP TO DISCUSS YOUR RIGHTS - SMLR

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SEMLER SCIENTIFIC TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS

SMLR SHAREHOLDER ACTION REMINDER: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SEMLER SCIENTIFIC

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SEMLER SCIENTIFIC TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SEMLER SCIENTIFIC BETWEEN MARCH 10, 2021 AND APRIL 15, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 23, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SEMLER SCIENTIFIC, INC. ("SEMLER SCIENTIFIC" OR THE "COMPANY") (NASDAQ: SMLR) AND REMINDS INVESTORS OF THE OCTOBER 28, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

INVESTOR DEADLINE APPROACHING: FARUQI & FARUQI, LLP INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SEMLER SCIENTIFIC

LOS ANGELES , OCT. 23, 2025 /PRNEWSWIRE/ --THE DJS LAW GROUP REMINDS INVESTORS OF A CLASS ACTION LAWSUIT AGAINST SEMLER SCIENTIFIC, INC. ("SEMLER " OR "THE COMPANY") (NASDAQ: SMLR ) FOR VIOLATIONS OF 10(B) AND 20(A) OF THE SECURITIES EXCHANGE ACT OF 1934 AND RULE 10B-5 PROMULGATED THEREUNDER BY THE U.S. SECURITIES AND EXCHANGE COMMISSION. SHAREHOLDERS WHO PURCHASED SHARES OF SMLR DURING THE CLASS PERIOD LISTED ARE ENCOURAGED TO CONTACT THE FIRM REGARDING POSSIBLE LEAD PLAINTIFF APPOINTMENTS.

FARUQI & FARUQI, LLP SECURITIES LITIGATION PARTNER JAMES (JOSH) WILSON ENCOURAGES INVESTORS WHO SUFFERED LOSSES IN SEMLER SCIENTIFIC TO CONTACT HIM DIRECTLY TO DISCUSS THEIR OPTIONS IF YOU PURCHASED OR ACQUIRED SECURITIES IN SEMLER SCIENTIFIC BETWEEN MARCH 10, 2021 AND APRIL 15, 2025 AND WOULD LIKE TO DISCUSS YOUR LEGAL RIGHTS, CALL FARUQI & FARUQI PARTNER JOSH WILSON DIRECTLY AT 877-247-4292 OR 212-983-9330 (EXT. 1310). [YOU MAY ALSO CLICK HERE FOR ADDITIONAL INFORMATION] NEW YORK , OCT. 15, 2025 /PRNEWSWIRE/ -- FARUQI & FARUQI, LLP, A LEADING NATIONAL SECURITIES LAW FIRM, IS INVESTIGATING POTENTIAL CLAIMS AGAINST SEMLER SCIENTIFIC, INC. ("SEMLER SCIENTIFIC" OR THE "COMPANY") (NASDAQ: SMLR) AND REMINDS INVESTORS OF THE OCTOBER 28, 2025 DEADLINE TO SEEK THE ROLE OF LEAD PLAINTIFF IN A FEDERAL SECURITIES CLASS ACTION THAT HAS BEEN FILED AGAINST THE COMPANY.

Semler Scientific, Inc.

SMLR

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Semler Scientific, Inc.

SMLR.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SMLR